Llwytho...
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Mol Ther Oncolytics |
|---|---|
| Prif Awduron: | , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Gene & Cell Therapy
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6300726/ https://ncbi.nlm.nih.gov/pubmed/30581986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2018.10.006 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|